Eli Lilly And Co (1LLY) Stock Price & News

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia

About Eli Lilly And Co

CEODavid A. Ricks

Employees50 мың

Founded1876

HeadquartersИндианаполис, Индиана, Америка Құрама Штаттары

SectorPharmaceutical industry

Websitelilly.com

All values in USD	2025 ж. қыр.	2025 ж. жел.	2026 ж. нау.	2026 ж. мау.
Revenue	17,60 млрд	19,29 млрд	19,80 млрд	22,97 млрд
Cost of goods sold	3,01 млрд	3,37 млрд	3,58 млрд	3,27 млрд
Cost of revenue	3,01 млрд	3,37 млрд	3,58 млрд	3,27 млрд
Research and development expenses	3,47 млрд	3,80 млрд	3,51 млрд	3,82 млрд
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	2,63 млрд	3,46 млрд	2,93 млрд	3,43 млрд
Operating expense	6,09 млрд	7,26 млрд	6,44 млрд	7,25 млрд
Total operating expenses	9,10 млрд	10,63 млрд	10,02 млрд	10,52 млрд
Operating income	8,50 млрд	8,66 млрд	9,78 млрд	12,46 млрд
Other non operating income	-9,10 млн	181,20 млн	170,00 млн	561,00 млн
EBT including unusual items	7,23 млрд	8,27 млрд	8,85 млрд	9,25 млрд
EBT excluding unusual items	8,21 млрд	8,89 млрд	9,71 млрд	12,73 млрд
Income tax expense	1,65 млрд	1,63 млрд	1,45 млрд	2,15 млрд
Effective tax rate	22,81%	19,70%	16,43%	23,27%
Other operating expenses	-	-	-	-
Net income	5,58 млрд	6,64 млрд	7,40 млрд	7,10 млрд
Net profit margin	31,72%	34,41%	37,36%	30,88%
Earnings per share	7,02	7,54	8,55	8,38
Interest and investment income	65,00 млн	672,40 млн	-	-
Interest expense	-179,60 млн	-153,30 млн	-332,00 млн	-345,00 млн
Net interest expenses	-114,60 млн	519,10 млн	-332,00 млн	-345,00 млн
Depreciation and amortization charges	-	-	-	-
EBITDA	8,97 млрд	9,25 млрд	10,29 млрд	12,99 млрд
Gain or loss from assets sale	-	-180,00 млн	-	-

Ask anything